See more : Cloudbreak Discovery Plc (CDBDF) Income Statement Analysis – Financial Results
Complete financial analysis of Apogee Therapeutics, Inc. (APGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apogee Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PennyMac Mortgage Investment Trust (PMT-PA) Income Statement Analysis – Financial Results
- Idorsia Ltd (IDIA.SW) Income Statement Analysis – Financial Results
- Valiant Co.,Ltd (002643.SZ) Income Statement Analysis – Financial Results
- Udemy, Inc. (UDMY) Income Statement Analysis – Financial Results
- TDH Holdings, Inc. (PETZ) Income Statement Analysis – Financial Results
Apogee Therapeutics, Inc. (APGE)
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Metric | 2023 | 2022 |
---|---|---|
Revenue | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 |
Gross Profit Ratio | 0.00% | 0.00% |
Research & Development | 68.42M | 27.79M |
General & Administrative | 24.58M | 2.94M |
Selling & Marketing | 0.00 | 0.00 |
SG&A | 24.58M | 2.94M |
Other Expenses | 0.00 | 0.00 |
Operating Expenses | 93.00M | 30.73M |
Cost & Expenses | 93.00M | 30.73M |
Interest Income | 9.02M | 92.00K |
Interest Expense | 0.00 | 9.15M |
Depreciation & Amortization | 9.02M | 33.52M |
EBITDA | -83.99M | 0.00 |
EBITDA Ratio | 0.00% | 0.00% |
Operating Income | -93.00M | -30.73M |
Operating Income Ratio | 0.00% | 0.00% |
Total Other Income/Expenses | 9.02M | -9.06M |
Income Before Tax | -83.99M | -39.79M |
Income Before Tax Ratio | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -33.52K |
Net Income | -83.99M | -39.79M |
Net Income Ratio | 0.00% | 0.00% |
EPS | -3.36 | -0.79 |
EPS Diluted | -3.36 | -0.79 |
Weighted Avg Shares Out | 25.01M | 50.67M |
Weighted Avg Shares Out (Dil) | 25.01M | 50.67M |
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
7 Biotech Stocks to Get In Now Before Investors Catch On
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing
Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports